Viewing Study NCT01719367



Ignite Creation Date: 2024-05-06 @ 1:00 AM
Last Modification Date: 2024-10-26 @ 10:58 AM
Study NCT ID: NCT01719367
Status: COMPLETED
Last Update Posted: 2019-06-17
First Post: 2012-10-29

Brief Title: Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
Sponsor: Vanderbilt University Medical Center
Organization: Vanderbilt University Medical Center

Study Overview

Official Title: Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
Status: COMPLETED
Status Verified Date: 2019-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Atrial fibrillation AF the most common sustained heart rhythm disorder is becoming increasingly prevalent in the Western world The number of people with AF in the United States is projected to roughly double by the year 2050 to an estimated 6-12 million For many patients with AF rate control with atrioventricular AV node blockers is a widely accepted therapeutic strategy These agents control heart rate thus preventing symptoms and systolic heart failure associated with tachycardia due to a rapid ventricular response to AF Beta-blockers are widely accepted as first line agents for rate control in AF especially when patients have concomitant hypertension HTN coronary artery disease cardiomyopathies or heart failure HF As a class beta-blockers are among the most commonly prescribed cardiovascular medications

Among patients with AF treated with beta-blockers the heart rate HR response varies substantially Sometimes adequate rate control can be achieved by titration of the beta-blocker dose but frequently additional AV nodal blockers andor digoxin are necessary In some cases adequate rate control cannot be achieved even with the simultaneous use of multiple AV nodal blockers necessitating mechanical ablation of the AV node and permanent pacemaker implantation

Patient-specific variables that influence the response to beta-blockers include comorbid conditions weight age and level of physical activity Ethnic differences in the response to beta-blockers for the treatment of HTN and HF are well-described However the contribution of genetic variants to beta-blocker efficacy in AF is unknown We propose to study whether the ADRB1 Gly389Asp SNP reduces response to beta-blockade in subjects with permanent AF
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None